Piramal Pops on US Zinc Injection Launch

17 Jan 2024 , 10:47 AM

Following the announcement by its Piramal Critical Care (PCC) business on the introduction of zinc sulphate injection in the US, shares of Piramal Pharma Limited saw an increase of more than one percent, closing at Rs 140 in early trade on January 17.

In an exchange statement on January 16, the business stated, ‘The launch will enable PCC further to expand their existing Zinc Sulphate Injection product line and overall the generic injectables portfolio.’

The share was down 0.5% from the previous closing at Rs 137.5 on the National Stock Exchange at 10:51 am. Over the last year, the stock has increased by almost 24%.

When oral or enteral nutrition is not feasible, insufficient, or inappropriate, zinc sulphate is recommended as a trace element for zinc nutrition in both adult and pediatric patients.

Zinc Sulphate for Injection, USP 10mg/10ml is the most recent medication to be introduced into the generic injectables market by Piramal Critical Care.

The business expanded its wide range of critical care medicines in 2023 with the introduction of Doxycycline for Injection, USP, and Pantoprazole Sodium for Injection, USP.

Peter DeYoung, CEO of Piramal Global Pharma, stated, ‘The introduction of Zinc Sulphate Injection expands our US portfolio of injectable products, complementing our inhaled anesthesia offerings.’

For feedback and suggestions, write to us at [e-mail]